Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Franck Dubin"'
Autor:
Paul G. Richardson, Aurore Perrot, Jesus San Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A. Dimopoulos, Shang-Yi Huang, Jiri Minarik, Michele Cavo, H. Miles Prince, Sandrine Macé, Rick Zhang, Franck Dubin, Mony Chenda Morisse, Kenneth C. Anderson
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
The primary and pre-specified updated analyses of ICARIA-MM (NCT02990338) demonstrated improved progression-free survival and a benefit in overall survival (OS) was reported with the addition of isatuximab, an anti-CD38 monoclonal antibody, to pomali
Externí odkaz:
https://doaj.org/article/2cdeb822507640969679ff3be53cc866
Autor:
Philippe Moreau, Aurore Perrot, Meletios A. Dimopoulos, Thomas Martin, Thierry Facon, Marcelo Eduardo Capra, Meral Beksac, Nicole Armstrong, Franck Dubin, Sandrine Macé, Marie-Laure Risse, Christina Tekle, Zandra Klippel, Paul Richardson
Publikováno v:
HemaSphere, Vol 7, p e27700c7 (2023)
Externí odkaz:
https://doaj.org/article/a771e98472aa4c73a829578fd9de0027
Autor:
Paul G. Richardson, Aurore Perrot, Jesús San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A. Dimopoulos, Jeffrey SY Huang, Jiri Minarik, Michele Cavo, H. Miles Prince, Sandrine Macé, Laure Malinge, Franck Dubin, Mony Morisse, Kenneth C. Anderson
Publikováno v:
Blood. 140:608-610
Autor:
Paul G Richardson, Aurore Perrot, Jesus San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A Dimopoulos, Jeffrey Shang-Yi Huang, Jiri Minarik, Michele Cavo, H Miles Prince, Laure Malinge, Franck Dubin, Helgi van de Velde, Kenneth C Anderson
Publikováno v:
The Lancet Oncology. 23:416-427
The primary analysis of the ICARIA-MM study showed significant improvement in progression-free survival with addition of isatuximab to pomalidomide-dexamethasone in relapsed and refractory multiple myeloma. Here, we report a prespecified updated over
Autor:
Douglas W. Sborov, Paul G. Richardson, Noopur Raje, Anita D'Souza, Rao Saleem, Frank Campana, Franck Dubin, Jacob P. Laubach, Giada Bianchi, Sascha A. Tuchman, Dheepak Kanagavel, Saad Z. Usmani, William I. Bensinger, Chatchada Karanes
Publikováno v:
Leukemia
Part B of this phase 1b study (ClinicalTrials.gov number, NCT02283775) evaluated safety and efficacy of a fixed-volume infusion of isatuximab, an anti-CD38 monoclonal antibody, in combination with pomalidomide and dexamethasone (Pd) in relapsed/refra
Autor:
Maria-Victoria Mateos, Paula Rodriguez Otero, Youngil Koh, Joaquin Martinez-Lopez, Gurdeep Parmar, H. Miles Prince, Hang Quach, Paz Ribas, Emil Hermansen, Vania T.M. Hungria, Sevgi Kalayoglu Besisik, Jin Seok Kim, Xavier Leleu, Valdas Pečeliūnas, Fredrik Schjesvold, Omur G. Sevindik, Tatiana Lavrova, Franck Dubin, Christine Devisme, Lucie Lepine, Sandrine Macé, Mony Morisse, Irene Ghobrial
Background: Results from a randomized, Phase 3 study by the Spanish Myeloma Group (PETHEMA/GEM) previously showed that treatment with lenalidomide plus dexamethasone (Rd) may delay progression to active disease in patients (pts) with high-risk smolde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a625388b7e086ccf704fd1a7a005cf9
https://hdl.handle.net/20.500.12511/10630
https://hdl.handle.net/20.500.12511/10630
Publikováno v:
Clinical journal of oncology nursing. 25(6)
Background Isatuximab is a CD38 monoclonal antibody approved for use in combination with pomalidomide plus dexamethasone to treat adults with relapsed/refractory multiple myeloma who have received at least two prior therapies. Because isatuximab is a
Autor:
Youngil Koh, Lucie Lepine, Miles Prince, Valdas Peceliunas, Sevgi Kalayoglu Besisik, Irene M. Ghobrial, Codina Oprea, Emil Hermansen, Javier de la Rubia, Vania Hungria, Hang Quach, Paula Rodriguez-Otero, Maria-Victoria Mateos, Jin Seok Kim, Christine Devisme, Joaquin Martinez-Lopez, Sandrine Macé, Gurdeep Parmar, Xavier Leleu, Fredrik Schjesvold, Franck Dubin
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S109-S110
Background: High-risk smoldering multiple myeloma (HR-SMM) is associated with a greater risk of progression to symptomatic disease, suggesting the need for early, efficacious therapeutic interventions to improve outcomes. The ongoing, randomized Phas
Autor:
Xavier Leleu, Aurore Perrot, Jesús F. San-Miguel, Jeffrey Shang Yi Huang, Kenneth C. Anderson, Michele Cavo, Helgi van de Velde, H. Miles Prince, Meral Beksac, Jiri Minarik, Fredrik Schjesvold, Philippe Moreau, Paul G. Richardson, Franck Dubin, Cheng Zheng, Meletios A. Dimopoulos, Ivan Spicka
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S423-S424
Background Isa is an approved monoclonal antibody that binds to a specific epitope on the CD38 receptor. Phase 3 ICARIA-MM study (NCT02990338) demonstrated improved progression-free survival (PFS) with Isa-Pd vs Pd (P=0.001) and manageable safety pro
Autor:
Moreau, Philippe, Perrot, Aurore, Dimopoulos, Meletios-Athanasios, Martin, Thomas, Facon, Thierry, Capra, Marcelo, Beksac, Meral, Armstrong, Nicole M, Pharm, Franck Dubin, Macé, Sandrine, Risse, Marie-Laure, Tekle, Christina, Klippel, Zandra, Richardson, Paul G.
Publikováno v:
In Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 1:S484-S484